Education
About Us
Working with TipRanks
Follow Us
DocMorris AG (CH:DOCM)
:DOCM
DOCM Stock Chart & Stats
Day’s Range― - ―
52-Week RangeCHF14.90 - CHF88.35
Previous CloseN/A
Volume45.75K
Average Volume (3M)147.68K
Market Cap
CHF283.16M
Enterprise ValueCHF837.85M
Total Cash (Recent Filing)CHF204.68M
Total Debt (Recent Filing)CHF355.73M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Aug 19, 2025EPS Estimate
-2.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.24
Shares Outstanding14,835,093
10 Day Avg. Volume140,089
30 Day Avg. Volume147,681
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF27.78Price Target Upside36.18% Upside
Rating ConsensusHold
Number of Analyst Covering9
---
DocMorris News
PremiumCompany Announcements
DocMorris Secures CHF 200 Million for Strategic GrowthPremiumCompany Announcements
Zur Rose Group AG: Cautious Optimism in Earnings Call
PremiumCompany Announcements
DocMorris Achieves 2024 Goals and Plans Capital Increase Amid Rx Growth---
Bulls Say, Bears Say
Bulls Say
Prescription Sales PerformanceThe company's Rx revenues were up 52% to CHF 53.9m, indicating strong performance in prescription sales.
Revenue GrowthDocMorris released 1Q25 prelims that are in line with expectations, with revenues increasing by 13.4% on a group level.
Telemedicine ExpansionThe telemedicine business was a bright spot as TeleClinic doubled its sales to CHF 11m with EBITDA of >CHF 3m.
Bears Say
Balance Sheet PressureThe balance sheet is under pressure, impacting potential for recovery.
Capital Raise ImpactFollowing a disappointing performance in 2024, especially in Rx, and in anticipation of a diluting capital increase, the shares have declined significantly.
Profitability ConcernsFor FY25, DOCM expects sales growth of over 10% and adjusted EBITDA of minus CHF 35 to minus CHF 55m, which appears cautious compared to consensus expectations.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
2.21%
Mutual Funds
<0.01% Other Institutional Investors
95.85% Public Companies and
Individual Investors
DOCM FAQ
What was DocMorris AG’s price range in the past 12 months?
DocMorris AG lowest stock price was CHF14.90 and its highest was CHF88.35 in the past 12 months.
What is DocMorris AG’s market cap?
DocMorris AG’s market cap is CHF283.16M.
When is DocMorris AG’s upcoming earnings report date?
DocMorris AG’s upcoming earnings report date is Aug 19, 2025 which is in 120 days.
How were DocMorris AG’s earnings last quarter?
DocMorris AG released its earnings results on Mar 13, 2025. The company reported -CHF5.02 earnings per share for the quarter, missing the consensus estimate of -CHF4.6 by -CHF0.42.
Is DocMorris AG overvalued?
According to Wall Street analysts DocMorris AG’s price is currently Undervalued.
Does DocMorris AG pay dividends?
DocMorris AG does not currently pay dividends.
What is DocMorris AG’s EPS estimate?
DocMorris AG’s EPS estimate is -2.7.
How many shares outstanding does DocMorris AG have?
DocMorris AG has 14,835,093 shares outstanding.
What happened to DocMorris AG’s price movement after its last earnings report?
DocMorris AG reported an EPS of -CHF5.02 in its last earnings report, missing expectations of -CHF4.6. Following the earnings report the stock price went down -28.693%.
Which hedge fund is a major shareholder of DocMorris AG?
Currently, no hedge funds are holding shares in CH:DOCM
---
Company Description
DocMorris AG
DocMorris AG operates e-commerce pharmacies and a wholesale business for medical and pharmaceutical products in Switzerland and internationally. The company offers prescription and over-the-counter medicines, consumer health products, beauty and personal care products, nutritional supplements, painkillers, and first aid products, as well as medicines management services. It also operates stationary pharmacy shops. The company sells its products directly to physicians, online mail-order pharmacies, and private individuals under the Zur Rose, PromoFarma, TeleClinic, and DocMorris brands. The company was formerly known as Zur Rose Group AG and changed its name to DocMorris AG in May 2023. DocMorris AG was founded in 1993 and is headquartered in Frauenfeld, Switzerland.
---
DOCM Stock 12 Month Forecast
Average Price Target
CHF27.78
▲(36.18% Upside)
Technical Analysis
Kuros Biosciences
―
IVF HARTMANN Holding AG
―
Galenica AG
―
Galderma Group AG
―
Medartis Holding AG
―
Best Analysts Covering DOCM
1 Year
1 Year Success Rate
30/40 ratings generated profit
1 Year Average Return
+25.62%
reiterated a sell rating last month
Copying Sebastian Vogel's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +25.62% per trade.
---